Adrestia Therapeutics News and Activities

Adrestia Therapeutics is owned by Insmed.

Insmed is one of the...

• Russell 3000;
• TOB Iconic 10,000.

Insmed is a company listed under the stock ticker INSM (US).

Insmed has a direct presence in 2 countries.

They are in:

• Pharmaceuticals50%
• Biotechnology50%

View the org chart displaying its 2 main executives

Most searched biographies at Adrestia Therapeutics

• Will Lewis, Chairman of the Board
• Joanna Green, Director

Create your alert
to follow the executive moves at Adrestia Therapeutics.

Insmed has 2,339 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Biogen (United States (USA)).

Popular M&A news in Biotechnology

• Stylus Medicine has just announced a $85 Million fundraising (posted on May 16 2025).
• Azafaros has just announced a $132 Million fundraising (posted on May 15 2025).
• The new name of Garuda Therapeutics is Stratus Therapeutics. (posted on May 12 2025).

Popular contacts in Biotechnology

• Sandra Smith - Senior Vice President, Clinical Solutions & Strategic Partnerships at WIRB-Copernicus Group
• Deepika Verma - Associate Director of Data Science and Digitalization at Wheeler Bio
• Steven Gillis - Chairman of the Board at VBI Vaccines

Learn more about the Biotechnology industry

Press releases by Adrestia Therapeutics

• Huntington’s disease progression stopped in cell study by University of Cambridge and UCL researchers

Social media about Adrestia Therapeutics

• Adrestia Therapeutics on Wikipedia, Google News & Yahoo Finance
• Adrestia Therapeutics on LinkedIn, Twitter & YouTube